is semaglutide still on shortage list the As of February 21, 2025, FDA updated its drug Federal judge upholds FDA's removal – FDA Ends Semaglutide Shortage Listing,

Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs

As a generically available med, it is no longer studied for further benefits

For us, GLP-1s, last year, were number 32, and this year theyre number one [in pharmacy spending]. Human Resources Director, health benefits administrator Before we knew it, we spent half a million dollars and were projected to go up to $1.2 million the following year. Manager of Compensation and Benefits Administration, large retail firm Ill just say our GLP-1 agonist spending year over year was increasing 50% for weight loss

Tirzepatide produced substantially greater weight loss (~78% additional) and superior glycemic control (~0.8% additional HbA1c reduction), yet the additional cardiovascular benefit over an already-active comparator was modest

In the current review, we will provide an overview of how the gutbrain axis contributes to metabolic homeostasis, highlighting some of the novel ideas as to how this gutbrain communication is mediated